200 related articles for article (PubMed ID: 17381379)
1. Angiotensin II receptor blockers for the treatment of heart failure: a class effect?
Hudson M; Humphries K; Tu JV; Behlouli H; Sheppard R; Pilote L
Pharmacotherapy; 2007 Apr; 27(4):526-34. PubMed ID: 17381379
[TBL] [Abstract][Full Text] [Related]
2. Examining the association of olmesartan and other angiotensin receptor blockers with overall and cause-specific mortality.
Lin JW; Chang CH; Caffrey JL; Wu LC; Lai MS
Hypertension; 2014 May; 63(5):968-76. PubMed ID: 24516110
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements.
Nishimura T; Hashimoto J; Ohkubo T; Kikuya M; Metoki H; Asayama K; Totsune K; Imai Y
Clin Exp Hypertens; 2005 Aug; 27(6):477-89. PubMed ID: 16081340
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure.
Desai RJ; Ashton CM; Deswal A; Morgan RO; Mehta HB; Chen H; Aparasu RR; Johnson ML
Pharmacoepidemiol Drug Saf; 2012 Mar; 21(3):233-40. PubMed ID: 21786364
[TBL] [Abstract][Full Text] [Related]
5. Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study.
Nishida Y; Takahashi Y; Susa N; Kanou N; Nakayama T; Asai S
Cardiovasc Diabetol; 2013 Nov; 12():159. PubMed ID: 24180232
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study.
Antoniou T; Camacho X; Yao Z; Gomes T; Juurlink DN; Mamdani MM
CMAJ; 2013 Sep; 185(12):1035-41. PubMed ID: 23836857
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
8. Palatability of angiotensin II antagonists among nephropathic children.
Meier CM; Simonetti GD; Ghiglia S; Fossali E; Salice P; Limoni C; Bianchetti MG;
Br J Clin Pharmacol; 2007 May; 63(5):628-31. PubMed ID: 17302913
[TBL] [Abstract][Full Text] [Related]
9. Association of treatment with losartan vs candesartan and mortality among patients with heart failure.
Svanström H; Pasternak B; Hviid A
JAMA; 2012 Apr; 307(14):1506-12. PubMed ID: 22496265
[TBL] [Abstract][Full Text] [Related]
10. Effect of switching from telmisartan, valsartan, olmesartan, or losartan to candesartan on morning hypertension.
Hasegawa H; Takano H; Kameda Y; Kubota A; Kobayashi Y; Komuro I
Clin Exp Hypertens; 2012; 34(2):86-91. PubMed ID: 22251314
[TBL] [Abstract][Full Text] [Related]
11. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals.
ARB Trialists Collaboration
J Hypertens; 2011 Apr; 29(4):623-35. PubMed ID: 21358417
[TBL] [Abstract][Full Text] [Related]
12. Association of candesartan vs losartan with all-cause mortality in patients with heart failure.
Eklind-Cervenka M; Benson L; Dahlström U; Edner M; Rosenqvist M; Lund LH
JAMA; 2011 Jan; 305(2):175-82. PubMed ID: 21224459
[TBL] [Abstract][Full Text] [Related]
13. Cardiology patient page. Angiotensin receptor blockers.
Terra SG
Circulation; 2003 Jun; 107(24):e215-6. PubMed ID: 12821593
[No Abstract] [Full Text] [Related]
14. [ARB II in chronic heart failure. Coincidences and divergences. Class effect?].
Barrios Alonso V; Escobar Cervantes C; Calderón Montero A
Rev Clin Esp; 2005 Oct; 205(10):499-506. PubMed ID: 16238962
[TBL] [Abstract][Full Text] [Related]
15. Switch strategies in the management of hypertension: a cost minimisation analysis of angiotensin receptor blocker based regimen.
Belsey JD
Curr Med Res Opin; 2008 Feb; 24(2):581-9. PubMed ID: 18198012
[TBL] [Abstract][Full Text] [Related]
16. The place of ARBs in heart failure therapy: is aldosterone suppression the key?
Markan U; Pasupuleti S; Pollard CM; Perez A; Aukszi B; Lymperopoulos A
Ther Adv Cardiovasc Dis; 2019; 13():1753944719868134. PubMed ID: 31401939
[TBL] [Abstract][Full Text] [Related]
17. A review of the current evidence for the use of angiotensin-receptor blockers in chronic heart failure.
Erhardt LR
Int J Clin Pract; 2005 May; 59(5):571-8. PubMed ID: 15857354
[TBL] [Abstract][Full Text] [Related]
18. Retrospective analysis of real-world efficacy of angiotensin receptor blockers versus other classes of antihypertensive agents in blood pressure management.
Petrella R; Michailidis P
Clin Ther; 2011 Sep; 33(9):1190-203. PubMed ID: 21885126
[TBL] [Abstract][Full Text] [Related]
19. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
[TBL] [Abstract][Full Text] [Related]
20. [Review of randomized trials of angiotensin receptor blockers in the treatment of patients with congestive heart failure].
Rakugi H; Ogihara T
Nihon Rinsho; 2001 Oct; 59(10):2051-61. PubMed ID: 11676153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]